MEDP — Medpace Holdings, Inc.

Medpace (MEDP) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $706.6 million, a year-over-year increase of 26.5% (25.8% on a constant currency basis).
• EBITDA: $149.4 million, up 25.9% from $118.6 million in Q1 2025; EBITDA margin at 21.1% (slightly down from 21.2% YoY).
• Net Income: $123.9 million, an 8.1% increase compared to $114.6 million in the prior year; net income per diluted share rose to $4.28 from $3.67.
• Cash Flow: Generated $151.8 million from operating activities; cash balance as of March 31, 2026, was $652.7 million.
• Backlog: Ending backlog was approximately $2.9 billion, a 2.9% increase YoY; net book-to-bill ratio was 0.88.

2. Strategic Updates and Business Highlights

• Cancellations: Cancellations reached their highest point in over a year, impacting net bookings which were below Q4 levels but above Q1 2025.
• New Business Awards: Net new business awards increased 23.7% YoY to $618.4 million.
• Pipeline Initiatives: The company is focused on expanding its pipeline and improving its win rate through various initiatives.
• Leadership Transition: Jesse Geiger, President, announced his retirement after 18.5 years with the company.

3. Forward Guidance and Outlook

• 2026 Guidance: Revenue, EBITDA, net income, and EPS guidance remain unchanged, based on an effective tax rate of 19%-20% and interest income of $27.5 million.
• Revenue Conversion: Approximately $1.94 billion of backlog is projected to convert to revenue in the next 12 months.

4. Bad News, Challenges, or Points of Concern

• Cancellation Rates: Increased cancellations are a significant concern, particularly in backlog, driven by project-specific issues rather than macroeconomic factors.
• Competitive Environment: There is a perception of increased competition in the biotech sector, which may affect Medpace's win rates.
• RFP Trends: Requests for proposals (RFPs) decreased both sequentially and year-over-year, raising concerns about future business opportunities.
• Revenue Growth Concerns: The company faces challenges in maintaining revenue growth due to a declining backlog coverage beyond one year and high cancellation rates.

5. Notable Q&A Insights

• Cancellations Dynamics: Cancellations were primarily due to product performance and project reprioritizations, with oncology and cardiovascular areas being most affected.
• Impact of M&A: Acquisitions in the biotech sector can lead to loss of future work for Medpace, although recent cancellations were not attributed to M&A activities.
• AI Investments: The company does not expect short-term productivity benefits from AI investments, anticipating that it will require significant investment before yielding net benefits.
• Hiring Despite Cancellations: Medpace continues to hire, signaling confidence in future revenue growth despite current challenges.
• Revenue Recognition: Revenue is recognized upon the first patient in, which means significant setup work has already been completed before cancellations occur.

This summary encapsulates the key points from Medpace's Q1 2026 earnings call, highlighting both the positive growth metrics and the challenges the company is currently facing.